BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3083526)

  • 1. Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro.
    Greer IA; Walker JJ; McLaren M; Calder AA; Forbes CD
    Thromb Res; 1986 Feb; 41(4):509-18. PubMed ID: 3083526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet aggregation in whole blood by adrenoceptor antagonists.
    Greer IA; Walker JJ; Calder AA; Forbes CD
    Thromb Res; 1985 Dec; 40(5):631-43. PubMed ID: 3937284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
    Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
    Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
    Onoda JM; Sloane BF; Honn KV
    Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls.
    Mehta J; Mehta P; Hay D
    Prostaglandins; 1982 Dec; 24(6):751-61. PubMed ID: 6820166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis.
    Jeremy JY; Barradas MA; Mikhailidis DP; Dandona P
    Drugs Exp Clin Res; 1985; 11(9):645-51. PubMed ID: 3939725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    GrodziƄska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation.
    Yamada Y; Furui H; Furumichi T; Suzuki T; Yamauchi K; Yokota M; Hayashi H; Saito H
    Jpn Heart J; 1990 Mar; 31(2):201-15. PubMed ID: 2113109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased platelet activity after termination of prostacyclin infusion into man.
    Dembinska-Kiec A; Zmuda A; Grodzinska L; Bieron K; Basista M; Kedzior A; Kostka-Trabka E; Telesz E; Zelazny T
    Prostaglandins; 1981 May; 21(5):827-32. PubMed ID: 6803307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
    Carter AJ; Heptinstall S
    Thromb Haemost; 1985 Oct; 54(3):612-6. PubMed ID: 3937261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro effect of amrinone on platelet aggregation in human whole blood.
    Pattison A; Eason CT; Bonner FW
    Res Commun Chem Pathol Pharmacol; 1986 Feb; 51(2):261-4. PubMed ID: 3083485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of calcium antagonists on platelet function and vascular prostacyclin production.
    Pirich C; Schmid P; Fitscha P; Wytek R; O'Grady J; Sinzinger H
    Blood Press Suppl; 1994; 1():75-80. PubMed ID: 8205307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function.
    Levin RI; Weksler BB; Jaffe EA
    Circulation; 1982 Dec; 66(6):1299-307. PubMed ID: 6291803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.